Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

• DOI: 10.1126/scitranslmed.aaf7779
• Publication Date: 2017-08-09T18:40:23Z
• Authors: Mohammad Alhadj Ali; Yuk-Fun Liu; Sefina Arif; Danijela Tatovic; Hina Shariff; Vivienne B. Gibson; Norkhairin Yusuf; Roman Baptista; Martin Eichmann; Nedyalko Petrov; Susanne Heck; Jennie H. M. Yang; Timothy I. M. Tree; Irma Pujol-Autonell; Lorraine Yeo; Lucas Baumard; Rachel Stenson; Alex Howell; Alison Clark; Zoe Boult; Jake Powrie; Laura Adams; Florence S. Wong; Stephen Luzio; Gareth Dunseath; Kate Green; Alison O’Keefe; Graham Bayly; Natasha Thorogood; Robert Andrews; Nicola Leech; Frank Joseph; Sunil Nair; Susan Seal; HoYee Cheung; Craig Beam; Robert Hills; Mark Peakman; Colin M. Dayan
• Keywords: Adult; Male; 0303 health sciences; Adolescent; C-Peptide; 610; Middle Aged; Autoantigens; T-Lymphocytes, Regulatory; Immunophenotyping; 3. Good health; Young Adult; 03 medical and health sciences; Diabetes Mellitus, Type 1; Double-Blind Method; 616; Journal Article; Humans; Female; Immunotherapy; Peptides; Autoantibodies; Proinsulin

Immunotherapy using peptide from the self-antigen proinsulin is safe in type 1 diabetes and is associated with changes in immune regulation.